Commit Biologics (“Commit”), a biotechnology company pioneering complement system activation and backed by €21.5 million in ...

COPENHAGEN, Denmark, March 11, 2026 (GLOBE NEWSWIRE)-- Commit Biologics (“Commit”), a biotechnology company pioneering complement system activation and backed by €21.5 million in seed financing from ...

The article, titled "Emerging roles of immune cell-derived neurotransmitters in immunity and disease," published on March 17, ...

Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...

The story of Q32 Bio, a company that develops therapeutics for inflammatory and autoimmune diseases, started two decades ago. That's when V. Michael Holers, MD, a University of Colorado School of ...

Among people with sickle cell disease—an inherited blood disorder—acute chest syndrome (ACS) is the leading cause of death. The condition is the result of red blood cells becoming stiff, sticky, and ...

Our immune system is armed with an array of defenses designed to detect and eliminate harmful threats. One of its most powerful defense mechanisms is the complement system-a group of proteins that ...

Amid these staggering projections, there are still many unknowns about neurodegenerative diseases and memory loss, but within ...